Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. reports clinical, regulatory and financing developments as a clinical-stage biopharmaceutical company using CRISPR gene editing and other core technologies. Its recurring updates center on in vivo and ex vivo therapeutic approaches for genetically defined diseases, including lonvoguran ziclumeran, or lonvo-z, for hereditary angioedema and nexiguran ziclumeran, or nex-z, for ATTR amyloidosis with cardiomyopathy and polyneuropathy.
Company announcements also cover Phase 3 clinical data, FDA interactions, biologics license application activity, quarterly financial results, common stock offerings, equity incentive grants and investor conference participation. These updates reflect Intellia's progress from gene-editing research and clinical development toward regulatory and commercial planning for its lead programs.
Intellia Therapeutics (Nasdaq: NTLA) reported that on August 1, 2026, it granted inducement equity awards to eight new employees under its 2024 Inducement Plan, as amended. The awards consist of time-based restricted stock units covering an aggregate of 38,200 shares of common stock, with one-third of the RSUs vesting annually over three years, subject to continued service. According to Intellia, these grants were made outside its stockholder-approved equity incentive plans under the 2024 Inducement Plan adopted in June 2024 and were approved by the compensation committee as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (Nasdaq: NTLA) reported second quarter 2026 results highlighted by positive Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema. A one-time infusion reduced attacks by 87% versus placebo over weeks 5–28, met all key secondary endpoints with p<0.0001, and showed no serious adverse events in the lonvo-z arm.
The company expects FDA acceptance of its lonvo-z BLA in the second half of 2026 and is planning for a potential U.S. launch in the first half of 2027. Intellia also advanced nexiguran ziclumeran (nex-z) Phase 3 ATTR programs, integrating new genomic insights and targeting MAGNITUDE-2 enrollment completion in the second half of 2026. Cash, cash equivalents and marketable securities were $628.4 million at June 30, 2026, supported by a $195 million equity offering and expected to fund operations at least into 2028.
Intellia Therapeutics (Nasdaq: NTLA) will host a conference call and webcast on August 6, 2026 at 8:00 a.m. ET to discuss its second quarter 2026 financial results and business updates. U.S. investors can dial 1-833-316-0545, international participants 1-412-317-5726, and a replay will be accessible for about 90 days via the Events page in the Investors & Media section of Intellia’s website.
Intellia Therapeutics (Nasdaq: NTLA) granted inducement equity awards to thirteen new employees on July 1, 2026, under its 2024 Inducement Plan.
The awards comprise time-based restricted stock units for an aggregate of 53,250 common shares, vesting in three equal annual installments, subject to continued service, and were approved under Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (Nasdaq: NTLA) reported additional positive Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema.
Lonvo-z achieved an 87% reduction in mean monthly attacks vs placebo and showed large decreases in treated and moderate/severe attacks, improved AE-QoL scores, favorable safety, and supports a rolling BLA with a potential U.S. launch targeted for 1H 2027.
Intellia Therapeutics (Nasdaq: NTLA) granted equity awards to six new employees under its 2024 Inducement Plan. On June 1, 2026, they received time-based RSUs for an aggregate 47,150 common shares, vesting in three equal annual installments over three years.
The awards were approved by the compensation committee as a material inducement to employment and granted outside stockholder-approved plans, in line with Nasdaq Listing Rule 5635(c)(4). Vesting requires continued service with Intellia.
Intellia Therapeutics (Nasdaq: NTLA) will present additional Phase 3 HAELO data for lonvoguran ziclumeran (lonvo-z), a CRISPR-based gene editing therapy for hereditary angioedema, in a late-breaking oral session at the EAACI 2026 Congress in Istanbul.
A related poster will address treatment burdens for HAE patients in Europe.
Intellia Therapeutics (Nasdaq: NTLA) reported Q1 2026 results and major clinical milestones. Cash, cash equivalents and marketable securities were $517.2M on March 31, 2026, plus ~$207M gross from an April equity offering, funding operations at least into 2028.
Lonvo-z achieved positive Phase 3 HAELO topline data in HAE, meeting its primary and all key secondary endpoints and supporting a rolling BLA, with a potential U.S. launch in the first half of 2027. The FDA lifted clinical holds on Phase 3 nex-z ATTR trials, and Q1 2026 net loss narrowed to $96.2M from $114.3M year over year.
Intellia Therapeutics (Nasdaq: NTLA) said management will participate in three upcoming investor fireside chats: Bank of America Securities Health Care Conference on May 12, 2026 (3:40 p.m. PT, Las Vegas); RBC Capital Markets Global Healthcare Conference on May 20, 2026 (2:35 p.m. ET, New York); and Jefferies Global Healthcare Conference on June 3, 2026 (4:55 p.m. ET, New York).
All sessions will be webcast live with replays available for approximately 90 days on Intellia’s Events and Presentations page at intelliatx.com.
Intellia Therapeutics (Nasdaq: NTLA) announced on May 1, 2026 that it granted inducement awards to 43 new employees under its 2024 Inducement Plan.
The awards are time-based RSUs totaling 208,850 shares, vesting one-third annually over three years, and were approved under Nasdaq Listing Rule 5635(c)(4) by the compensation committee.